This study demonstrates that rice pigmentation significantly influences metabolic response, with black rice exhibiting a low glycemic index (49), while red and white varieties recorded medium and high GI values, respectively. Although all varieties maintained a medium glycemic load, the superior profile of pigmented rice suggests it is a viable dietary tool for managing blood glucose and reducing the risk of chronic diseases. These findings advocate for the promotion of locally grown pigmented varieties as healthier alternatives to conventional white rice in the Filipino diet.

"Increasing ascorbate caused spurious decreases in blood lactate measured by the colorimetric assay and two POC devices (Epoc® and the StatStrip Xpress®). False increases in blood lactate were observed with one POC device (iSTAT 1®) and with two blood gas analysers (RAPIDPoint® 500 and Radiometer ABL90 Flex), although the latter was not clinically significant. The StatProfile® Prime Plus blood gas analyser showed no interference. For glucose, increasing ascorbate caused spurious elevations in glucose with four POC glucometers (FreeStyle Optium Neo, StatStrip Xpress®, HemoCue® Glucose 201, and Epoc®) and a false decrease with the RAPIDPoint® 500. No interference was observed with the StatProfile® Prime Plus, Radiometer ABL90 Flex, or laboratory assay. At pharmacologic concentrations, ascorbate can cause both falsely high and low lactate and glucose readings, depending on the device used. These findings help inform the selection of appropriate devices for future clinical trials of mega-dose ascorbate."

"SPHMMC manages large numbers of health commodities (more than 500 excluding program commodities) which necessitate efficient inventory management practice in place. However, the purchase of the commodities particularly those products used for laboratory diagnosis is not strictly based on the hospital's VEN list, indicating the need for better communication of the laboratory unit with the Drug and Therapeutic Committee (DTC) of the hospital. The DTC of the hospital should update the VEN list of the health commodities and strictly enforce the hospital procurement to adhere to the agreed upon list of medicines. In addition, the hospital should prioritize and decide the quantity and frequency of ordering health commodities based on regular ABC-VEN results."

"The ADA/WHO proposed cut-off of 6.5% (48 mmol/mol) for HbA1c was adequate to detect diabetes among the Xavante. However, the performance of the ADA proposed cut-off points for pre-diabetes, when used to detect IGT was inadequate and should not be recommended."

While capillary and venous glucose levels measured by the HemoCue 201+ system are strongly correlated, capillary values are consistently higher, especially in the non-fasting state. These discrepancies can lead to diagnostic errors near WHO cut-off points, suggesting that while capillary measurements are useful for group studies, they lack the precision required for individual clinical diagnosis.

"Given correct training and the establishment of a system of quality assurance, pharmacies are capable of obtaining glucose measurements that can be used as comparison measurements for controlling patients' meters. The pharmacies had external quality-assessment results comparable to general practice."

"A community pharmacy-based quality assessment procedure of patients' self monitoring of blood glucose significantly reduced the number of user errors. The analytical quality of the patients' measurements was good and did not improve further during the study. The high analytical quality might be explained by a selection bias of participating patients. Patients also reported increased confidence in their blood glucose measurements after their measurements had been assessed at the pharmacy."

"The Wondfo G6PD/Hb Test demonstrates good diagnostic performance using current manufacturer thresholds [reference testing for G6PD and Hb (spectrophotometer, Pointe Scientific, USA and HemoCue [HemoCue AB, Sweden)] across various conditions and both venous and capillary specimens. Comparable performance in both specimen types supports matrix equivalence. Usability is acceptable for end users, though refinements were recommended."

"In this study, HC201+ [HemoCue® Glucose 201+] showed a high level of accuracy irrespective of the sample type (capillary or venous). In contrast, HC201RT [HemoCue® Glucose 201 RT] measurement results were markedly affected by the type of sample."

"The HemoCue Glucose 201RT system is accurate, with small nonsystematic deviations, when compared with the commonly used HemoCue Glucose 201+. It is predicted that the HemoCue Glucose 201RT, which is more user friendly, will be a preferred alternative to the HemoCue Glucose 201+."

"In the present study the three glucose meters [Contour®, Accu-Chek® aviva und Free-Style® lite] provided good agreement with the reference [HemoCue® Glucose 201+ System] and reliable results in daily clinical routine. Overall, the Free-Style® [lite] and Accu-Chek® [aviva] device slightly outperformed the Contour® device."

"The Enlite sensor [the Enlite(™) sensor attached to an iPro recorder was compared against the HemoCue(®) model 201 glucose analyzer] performed adequately during acute pressure changes and was more accurate during hyperbaric than hypobaric conditions. Prewetting the sensors did not improve accuracy. Further studies on type 1 diabetes subjects are needed under various pressure conditions."

"All three meters [HemoCue Glucose 201 (Hemocue AB, Ängelhom, Sweden), Accu-Chek Performa (Roche Diagnostics, Basel Switzerland)] are sufficiently accurate and precise for in-hospital use. Because of possible interference by galactosemia or high hematocrit, the Accu-Chek is not the safest option for neonatal use. Patients receiving high doses of maltose in therapeutic infusions may still be at risk of being falsely classified as euglycemic or hyperglycemic with the reformulated Accu-Chek strips, and clinical evaluation of these strips in patients receiving maltose-containing infusions is urgently needed."

"The presented methodology shows that increased accuracy was indeed achieved by combining multi-technology and multi-sensors. The approach of integration contributes to increasing the signal-to-noise ratio (glucose to other contributors). A combination of several technologies allows compensation of a possible aberration in one modality by the others, while multi-sensor implementation enables corrections for interference contributions. Furthermore, clinical trials [comparing the GlucoTrack glucose monitor against HemoCue (Glucose 201+)] indicate the ability of using the device for a wide range of demography, showing clearly that the calibration is valid for long term."

"Integrating several modalities for NI assessment of glucose level enables more accurate readings, while a possible aberration in one modality is bypassed by the others. The present generation of GlucoTrack gives promising results [compared with Ascensia Elite (Bayer) and HemoCue (Glucose 201+)]; however, further improvement of the accuracy of the device is needed."

"The FSM [FreeStyle Mini] provides accurate results and constitutes a suitable alternative for bedside blood glucose measurements in experimental procedures [im Vergleich zum HemoCue Glucose 201 DM Analyzer und dem YSI 2300 STAT Glucose Oxidase Analyzer], helping to reduce sample size, turnaround time, and cost."

"Between-lot variation [for the Accu-Chek Sensor, Precision Xtra, Ascensia Elite, and HemoCue 201 glucometers] may influence participant EQA results for participant and method assessments. The clinical relevance of between-lot variation discovered in EQAS using noncommutable control materials should be examined by use of native blood samples."

The STANDARD G6PD Test [compared with spectrophotometric G6PD reference assay (Pointe Scientific), HemoCue 201+, and fluorescent spot test] is a promising tool to aid in POC detection of G6PD deficiency in Brazil.

"A substantial positive bias was found for CL measurements resulting in overdiagnosis of GDM. Our findings suggest better performance of HC201RT than HC201+ in GDM diagnosis. The results may have possible implications for GDM diagnosis in Sweden and require further elucidation."

The Accuracy of Point-of-Care Equipment for Glucose Measurement in Screening for Dysglycemia in Patients with Coronary Artery Disease.

"We conclude that HemoCue glucose 201+ analyser appears to be a suitable point of care (POC) blood glucose measurement device in neonates on both capillary and venous blood samples, as it showed a good correlation with central laboratory values without significant interference from Hct."